FDA approves AZ's Lumoxiti in hairy cell leukaemia
14 September 2018 07:00 BST US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk)for certain patients with relapsed or refractory hairy cell leukaemia Approval of Lumoxiti, a first-in-class medicine for hairy cell leukaemiamarks first new treatment option for patients in over 20 years1 75% of patients receiving Lumoxiti achieved anoverall response; 30% had a durable complete response2 AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-